FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for selecting a peptide with a high predicted solubility in an aqueous composition for producing vaccines against neoplasia. The peptide solubility in an aqueous composition is predicted by determining whether the combination of calculated isoelectric point (hereinafter – pI) and hydrophobicity (hereinafter – HYDRO) of the specified peptide is limited with pI ≥ 5 and HYDRO ≥ -6.0; pI ≥ 8 and HYDRO ≥ -8.0; pI ≤ 5 and HYDRO ≥ -5; pI ≥ 9 and HYDRO ≤ -8.0; or pI > 7 and HYDRO with the value of ≥ -5.5. Each amino acid in the specified peptide is assessed by its hydrophilicity value according to the table 11, and HYDRO is the sum of hydrophilicity values of a continuous section of amino acids in the peptide, all of which have the most negative hydrophilicity values less than 0, with the largest negative value. The peptide soluble in an aqueous composition is selected, if the combination of isoelectric point (pI) and hydrophobicity (HYDRO) of the specified peptide is limited with pI ≥ 5 and HYDRO ≥ -6.0; pI ≥ 8 and HYDRO ≥ -8.0; pI ≤ 5 and HYDRO ≥ -5; pI ≥ 9 and HYDRO ≤ -8.0; or pI > 7 and HYDRO with the value of ≥ -5.5. The peptide can be a neo-antigenic peptide for a vaccine against neoplasia.
EFFECT: inventions make it possible to project a peptide with a higher predicted solubility or reject potential peptides as those with improbable solubility.
14 cl, 15 dwg, 13 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
NEOANTIGENS AND THEIR APPLICATION METHODS | 2017 |
|
RU2773273C2 |
NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO CD22 | 2018 |
|
RU2797348C2 |
ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
Authors
Dates
2021-08-12—Published
2016-06-09—Filed